Latest / This Week In Medicine / 10 21 2025

Transcript

10 21 2025 · This Week In Medicine

• 0:00
  [SPEAKER_00]: Welcome to this week in medicine, your filtered medical journal summary.
• 0:03
  [SPEAKER_00]: Looking to stay up to date with the latest medical research but short on time?
• 0:07
  [SPEAKER_00]: This week in medicine has you covered.
• 0:09
  [SPEAKER_00]: Our AI-generated podcast provides you with a convenient, on the go-solution to keep you informed about the most significant developments in the medicine field.
• 0:16
  [SPEAKER_00]: Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers.
• 0:24
  [SPEAKER_00]: With this week in medicine, listening is faster than reading, and you can consume valuable medical knowledge while commuting, exercising, or during your daily routine.
• 0:32
  [SPEAKER_01]: Hi, this week in Medicine, we will be discussing.
• 0:35
  [SPEAKER_01]: First we will be discussing articles in New England Journal of Medicine.
• 0:39
  [SPEAKER_01]: Sentinel-Limph node biopsy alone or with lymphedinectomy and cervical cancer.
• 0:44
  [SPEAKER_01]: Background Limited data are available on survival outcomes after Sentinel-Limph node biopsy alone as compared with lymphedinectomy and cervical cancer conclusions.
• 0:55
  [SPEAKER_01]: In patients with early stage cervical cancer, Sentinel lymph node biopsy alone was not inferior to lymphadenectomy with respect to disease-free survival and was associated with fewer complications.
• 1:13
  [SPEAKER_01]: A phase 3 trial of teletaseept for systemic lupus erythematosis.
• 1:18
  [SPEAKER_01]: Background.
• 1:19
  [SPEAKER_01]: Teletaseept, a new dual inhibitor of the cytokines be lymphocytes stimulator, flies, and April, a proliferation inducing ligand, showed efficacy in adults with active systemic lupus erythematosis, SLE, in a phase 2B trial when added to standard therapy conclusions.
• 1:38
  [SPEAKER_01]: In this 52-week trial involving participants with active SLE who were receiving background therapy, the incidence of a clinical response was higher with teletocept than with placebo.
• 1:49
  [SPEAKER_01]: However, the incidence of upper respiratory infections, reduced immunoglobulin levels, and injection site reactions was also higher with teletocept.
• 2:04
  [SPEAKER_01]: Long-term safety and efficacy of gene therapy for a denocene deaminase deficiency.
• 2:09
  [SPEAKER_01]: Background.
• 2:11
  [SPEAKER_01]: Severe combined immunodeficiency, SCID, due to a denocene deaminase, ADA, deficiency, ADA said, is a life-threatening inborn error of immunity for which lentiviral gene therapy has been investigated in clinical trials' conclusions.
• 2:27
  [SPEAKER_01]: These long-term findings in a large patient cohort show the sustained clinical efficacy and safety of autologous CD-34, plus hematopoietic stem cell lente viral gene therapy for adacid, indicating that it is a curative treatment.
• 2:48
  [SPEAKER_01]: Mass administration of Azith Ramaisan to infants in Mali to reduce mortality.
• 2:53
  [SPEAKER_01]: Background.
• 2:54
  [SPEAKER_01]: Mass administration of Azith Ramaisan to children 1 to 59 months of age has been shown to reduce mortality among infants and children in this age group.
• 3:03
  [SPEAKER_01]: In some areas of Sub-Saharan Africa, the largest effects have appeared to be among infants younger than 12 months of age.
• 3:10
  [SPEAKER_01]: Within three months after treatment, this observation motivated the design of the current trial to conclusions.
• 3:16
  [SPEAKER_01]: Mass administration of Azith Ramaisin and Molly, limited to infants 1 to 11 months of age, did not result in lower infant or child mortality than placebo, regardless of whether Azith Ramaisin was delivered twice yearly or quarterly.
• 3:37
  [SPEAKER_01]: Next, we will be discussing articles from Journal of American Medical Association.
• 3:41
  [SPEAKER_01]: Interarterial Autoplases, after successful end-of-ascular repreusion in acute stroke.
• 3:47
  [SPEAKER_01]: The Pearl Randomized Clinical Trial.
• 3:50
  [SPEAKER_01]: Question.
• 3:51
  [SPEAKER_01]: Does Interarterial Autoplases after successful repreusion by mechanical thrombectomy?
• 3:56
  [SPEAKER_01]: Improve functional outcomes in patients with acute, anterior circulation, large vessel occlusion stroke, findings.
• 4:04
  [SPEAKER_01]: In this randomized clinical trial that included 324 patients, 44.8 percent of patients in the inter-artarial autoplay's group, achieved a modified rank in scale score of 0 or 1 at 90 days, indicating an excellent outcome, compared with 30.2 percent in the standard treatment group.
• 4:26
  [SPEAKER_01]: 1.45, meaning among patients with acute anterior circulation, large vessel occlusion stroke, who achieved successful endovascular reperfusion by mechanical thrombectomy, intra-artarial autoplases resulted in a higher likelihood of excellent functional outcome at 90 days.
• 4:49
  [SPEAKER_01]: Next we will be discussing articles from Annals of Internal Medicine.
• 4:53
  [SPEAKER_01]: Effectiveness of Recomponent Herpes Zoster Vaccine in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prioracy to Livestr vaccine.
• 5:04
  [SPEAKER_01]: Background Recomponent Zoster Vaccine, RZV, was preferentially recommended over Livestr vaccine,
• 5:15
  [SPEAKER_01]: To assess RZV effectiveness using target trial emulation, accounting for prior receipt of ZVL and immunocompetence conclusion.
• 5:24
  [SPEAKER_01]: Recomponent Zoster vaccine is effective in older adults, including immunocompromised adults, and two doses were more effective than one.
• 5:33
  [SPEAKER_01]: Prior ZVL recipients should be re-vaccinated with RZVL.
• 5:42
  [SPEAKER_01]: Next we will be discussing articles from British Medical Journal.
• 5:46
  [SPEAKER_01]: Sodium glucose co-transporter 2 inhibitors and risk of autoimmune rheumatic diseases, population-based cohort study.
• 5:54
  [SPEAKER_01]: Abstract.
• 5:55
  [SPEAKER_01]: Objective to evaluate the use of sodium glucose co-transporter 2, SGLT2, inhibitors and risk of autoimmune rheumatic diseases in adults with type 2 diabetes, conclusions.
• 6:07
  [SPEAKER_01]: In this large cohort of adults with type 2 diabetes, SGLT-2 inhibitors were associated with an 11% lower risk of autoimmune rematic diseases compared with sulfonoloreas.
• 6:19
  [SPEAKER_01]: These results suggest that SGLT-2 inhibitors may contribute to reducing the risk of autoimmune diseases.
• 6:26
  [SPEAKER_01]: This potential benefit, however.
• 6:27
  [SPEAKER_01]: should be carefully weighed against known adverse events and concerns about tolerability, replication in other populations and settings, as well as studies and patients with existing autoimmune-romatic diseases, are warranted to confirm and extend these observations.
• 6:49
  [SPEAKER_01]: Next we will be discussing articles from Lancet.
• 6:52
  [SPEAKER_01]: The Global Regional and National burden of Cancer, 1990 to 2023, with forecast to 2050, a systematic analysis for the Global burden of Disease Study 2023.
• 7:04
  [SPEAKER_01]: Backgrounded.
• 7:05
  [SPEAKER_01]: Cancer is a leading cause of death globally.
• 7:08
  [SPEAKER_01]: Accurate cancer burden information is crucial for policy planning, but many countries do not have up-to-date cancer surveillance data.
• 7:15
  [SPEAKER_01]: To inform global cancer control efforts, we used the global burden of diseases, injuries, and risk factor study, GPD.
• 7:23
  [SPEAKER_01]: 2023 framework to generate and analyze estimates of cancer burden for 47 cancer types or groupings by age, sex, and 204 countries and territories from 1990 to 2023.
• 7:35
  [SPEAKER_01]: Cancer burden attributable to selected risk factors from 1990 to 23.
• 7:39
  [SPEAKER_01]: And forecasted cancer burden up to 2050.
• 7:43
  [SPEAKER_01]: Cancer is a major contributor to global disease burden, with increasing numbers of cases and deaths forecasted up to 2050, and a disproportionate growth in burden in countries with scarce resources.
• 7:55
  [SPEAKER_01]: The decline in age standardized mortality rates from cancer is encouraging, but insufficient to meet the SDG target set for 2030.
• 8:02
  [SPEAKER_01]: Effectively and sustainably addressing cancer burden, globally will require comprehensive national and international efforts that consider health systems and context in the development and implementation of cancer control strategies across the continuum of prevention, diagnosis and treatment.
• 8:25
  [SPEAKER_01]: Next we will be discussing articles in the field of hematology.
• 8:29
  [SPEAKER_01]: Here are the articles from Jamma Oncology.
• 8:32
  [SPEAKER_01]: Pathogenic variants, family history, and cumulative risk of breast cancer in U.S. women.
• 8:39
  [SPEAKER_01]: Question.
• 8:40
  [SPEAKER_01]: How do variants in predisposition genes?
• 8:42
  [SPEAKER_01]: Family history, and other factors, impact breast cancer risk in the general U.S. population, findings.
• 8:49
  [SPEAKER_01]: In this study, including 67,692 women, those with a pathogenic variant, PV, and a first degree family history of breast cancer.
• 8:58
  [SPEAKER_01]: had an estimated 22.5% risk of breast cancer by age 50 years, at a 51.2% risk between age 50 and 80 years, compared with an estimated 9.4% risk by age 50 years, and 29.7% risk between ages 50 and 80 years in women with a PV but no family history.
• 9:18
  [SPEAKER_01]: PVs were rare.
• 9:19
  [SPEAKER_01]: Risk among PV carriers varied by family history and other factors, meaning women with PVs can use these risk estimates to guide screening and prevention decisions.
• 9:35
  [SPEAKER_01]: Next we will be discussing articles in the field of gastroenterology.
• 9:39
  [SPEAKER_01]: Here are the articles from gastroenterology.
• 9:41
  [SPEAKER_01]: efficacy of acupuncturary in irritable BL side-drome, action, a multi-center randomized controlled trial.
• 9:49
  [SPEAKER_01]: Background and aims.
• 9:51
  [SPEAKER_01]: Irritable bowel syndrome, IBS, affects 4.1% of the adult population, with many reporting ongoing symptoms despite first-line therapies.
• 10:01
  [SPEAKER_01]: Acupuncture is widely used for IBS, but without sufficient evidence.
• 10:06
  [SPEAKER_01]: We aimed to assess the efficacy of acupuncture in patients with diarrhea predominant IBS, IBSD, conclusions.
• 10:14
  [SPEAKER_01]: Acupuncture improved abdominal pain and stool consistency in patients with IBSD, with sustained efficacy over 18 weeks.
• 10:22
  [SPEAKER_01]: The results of this trial suggest that acupuncture may
• 10:34
  [SPEAKER_01]: Here are the articles from clinical gastroenterology.
• 10:37
  [SPEAKER_01]: Safety and efficacy of endoscopic sub-mucosal dissection for rectile neoplasms extending to the dentate line, a systematic review and meta-analysis.
• 10:47
  [SPEAKER_01]: Objective.
• 10:48
  [SPEAKER_01]: Endoscopic sub-mucosal dissection, ESD, is a superior, minimally invasive technique compared with other snare-based and escopic resection techniques for rectile neoplasms extending to the dentate line,
• 11:02
  [SPEAKER_01]: However, performing a successful ESD in the anal canal can be challenging due to masculinity and limited scope stability.
• 11:10
  [SPEAKER_01]: In this meta-analysis, we aim to evaluate the safety and efficacy of ESD for R&DLs conclusions.
• 11:18
  [SPEAKER_01]: ESD is a safe and effective option for managing R&DLs with a low recurrence rate.
• 11:23
  [SPEAKER_01]: Adversive ends such as post-precedural perianyl pain, post-precedural bleeding, and anal stenosis seem to be more common compared with colorectal ESD done for more proximal lesions.
• 11:35
  [SPEAKER_01]: However, these can typically be managed conservatively or with minimally invasive and escopic techniques.
• 11:47
  [SPEAKER_01]: Next we will be discussing articles in the field of infectious diseases.
• 11:51
  [SPEAKER_01]: Here are the articles from Clinical Infectious Diseases.
• 11:55
  [SPEAKER_01]: Dal Utegraviar slash lami-vudin.
• 11:58
  [SPEAKER_01]: For maintenance of virological suppression and persons with historical suspected or confirmed resistance to lami-vudin, weak 48 results of a single arm, open label, multi-center, phasia clinical trial.
• 12:11
  [SPEAKER_01]: Background
• 12:12
  [SPEAKER_01]: We investigated the efficacy of dollyutegrevere slash lami-vudin, for maintenance treatment for people with human immunodeficiency virus, HIV, PWH, and previous lami-vudin resistance-dots conclusions.
• 12:26
  [SPEAKER_01]: After excluding lami-vudin mutations in Proviro DNA by population sequencing, dollyutegrevere slash lami-vudin,
• 12:34
  [SPEAKER_01]: Effectively maintained viralogical suppression in PWH, with CD4 plus greater than 200 cells slash M3, and history of lemme view dean resistance.
• 12:44
  [SPEAKER_01]: Notably, no treatment emergent resistance was observed.
• 12:53
  [SPEAKER_01]: Next we will be discussing articles in the field of rheumatology.
• 12:56
  [SPEAKER_01]: Here are the articles from Journal of Clinical rheumatology.
• 13:00
  [SPEAKER_01]: Knowledge and behaviors in reproductive health among Mexican women with autoimmune rheumatic diseases, cross-sectional study.
• 13:07
  [SPEAKER_01]: Background Reproductive health is a critical issue for women with autoimmune rheumatic diseases.
• 13:13
  [SPEAKER_01]: ARDs, yet significant gaps in knowledge and practices persist.
• 13:18
  [SPEAKER_01]: While prior studies have largely focused on populations in high-income countries or specialized clinics, there is limited evidence addressing the reproductive health behaviors and challenges in middle-income settings where disparities in health care access and counseling are pronounced.
• 13:33
  [SPEAKER_01]: This study aims to assess reproductive health knowledge, contraceptive use,
• 13:41
  [SPEAKER_01]: Identifying specific areas for improvement in education, and counseling to bridge these gaps conclusions.
• 13:48
  [SPEAKER_01]: This study identified critical deficiencies in reproductive health knowledge, limited pregnancy planning among Mexican women with ARDs, and that half of the participants reported inconsistent contraceptive use, underscoring a significant gap in counseling and guidance.
• 14:03
  [SPEAKER_01]: The findings emphasize the need for targeted educational programs and standardized counseling protocols, to improve global reproductive health guidance provided by health care professionals.
• 14:19
  [SPEAKER_01]: Next we will be discussing articles in the field of cardiology.
• 14:22
  [SPEAKER_01]: Here are the articles from circulation.
• 14:25
  [SPEAKER_01]: Contemporary burden of cardiovascular disease and pregnancy.
• 14:28
  [SPEAKER_01]: Insights from a real-world pregnancy electronic health record cohort.
• 14:33
  [SPEAKER_01]: Background
• 14:34
  [SPEAKER_01]: Cardiac and vascular complications are the leading causes of maternal mortality and morbidity.
• 14:40
  [SPEAKER_01]: But the contemporary burden of and secular trends in pregnancy, related cardiovascular complications are not well characterized.
• 14:48
  [SPEAKER_01]: We developed a multi-institutional electronic health record-based pregnancy cohort, with rigorously defined cardiovascular outcomes to examine trends in prevalence of
• 15:01
  [SPEAKER_01]: CVD, and Incidents of Pregnancy-related cardiovascular complications.
• 15:06
  [SPEAKER_01]: In a large-scale electronic health record-based pregnancy cohort, both the prevalence of maternal cardiovascular comorbidities, and CVD, as well as the Incidents of Pregnancy-related cardiovascular complications within one year, postpartum increased over the course of two decades.
• 15:23
  [SPEAKER_01]: Our findings demonstrate an alarming rise in pregnancy-related cardiovascular complications in a contemporary real-world setting and highlight pregnancy as a crucial life opportunity for cardiovascular health optimization.
• 15:42
  [SPEAKER_01]: from jamacardiology.
• 15:44
  [SPEAKER_01]: Efficacy and tolerability of Feneranone according to the use and dosage of diureticsa pre-specified analysis of the Finearts HF randomized clinical trial.
• 15:55
  [SPEAKER_01]: Question.
• 15:55
  [SPEAKER_01]: What are the safety and efficacy of Feneranone in patients with heart failure with mildly reduced or preserved ejection fraction, hefmerf slash f-pef, receiving background diuretics, findings.
• 16:08
  [SPEAKER_01]: In this pre-specified secondary analysis of patients with HuffMorF slash F-PF in the Finiert's HF randomized clinical trial, the efficacy and safety of Fineranon were consistent across subgroups defined by diuretic use, including those receiving only loop diuretics, less than or equal to 40 milligrams and greater than 40 milligrams of furosamide equivalent, only non-loop diuretics and a combination of both.
• 16:33
  [SPEAKER_01]: Phenharonone reduced the need for loop diuretic dose intensification and decreased the mean loop diuretic dose compared to placebo.
• 16:41
  [SPEAKER_01]: Meaning these findings demonstrate a diuretic sparing effect of Phenharonone in patients with Huffmoref slash F-PF.
• 16:53
  [SPEAKER_01]: Next, we will be discussing articles in the field of endocrinology.
• 16:57
  [SPEAKER_01]: Here are the articles from Journal of Clinical Endocrinology and Metabolism.
• 17:01
  [SPEAKER_01]: Evaluation of Aldosterone's Suppression by Senair Azin, a punitive calf 1.3 inhibitor.
• 17:08
  [SPEAKER_01]: Context.
• 17:09
  [SPEAKER_01]: Primary auto-sterionism, PA, is commonly caused by somatic mutations of Kakna 1D encoding Kav 1.3, one of the four L-type calcium channels.
• 17:20
  [SPEAKER_01]: The over-the-counter drug, Senairazin, fits the Kav 1.3 Crystal Structure Poor Domain.objective.
• 17:27
  [SPEAKER_01]: We hypothesized that Kav 1.3 blockade by Senairazin
• 17:31
  [SPEAKER_01]: May achieve similar or greater reduction in our Dostorone secretion, the non-selective calf 1.21.3 blockade, by knife-edipine conclusion.
• 17:41
  [SPEAKER_01]: A calf 1.3 ligand, sinerosene, reduced all Dostorone secretion from adrenal cortical cells, but at maximum soluble concentrations was less effective than the non-selective calcium blocker, knife-edipine.
• 17:59
  [SPEAKER_01]: And, as in vitro, was inferior to nifetipine.
• 18:03
  [SPEAKER_01]: The limited efficacy of high dose nifetipine may be due to incomplete calf 1.3 blockade, or to a role for non-altyp calcium channels in aldosterone secretion.
• 18:20
  [SPEAKER_01]: Next we will be discussing articles in the field of pulmonary and critical care.
• 18:25
  [SPEAKER_01]: Here are the articles from chest.
• 18:27
  [SPEAKER_01]: The association between mechanical power within the first 24 hours and ICU mortality in mechanically ventilated adult patients with acute hypoxemic respiratory failure.
• 18:37
  [SPEAKER_01]: Background Despite the widespread adoption of lung-protective ventilation strategies, mortality
• 18:46
  [SPEAKER_01]: IMV remains high, mechanical power, MP, integrates various variables responsible for ventilator induced lung injury, and has been associated with mortality in patients with ARDS.
• 18:59
  [SPEAKER_01]: However, the impact of MP on ICU mortality in the larger group of patients with acute hypoxemic respiratory failure, AHRF, has not been well-established, and previous studies have reported
• 19:15
  [SPEAKER_01]: In this study, exposure to high MP within the first 24 hours of IMV was associated with increased ICU mortality and patients with AHRF.
• 19:25
  [SPEAKER_01]: The absence of a consistent safe threshold suggests that reducing MP at IMV initiation may be a strategy to improve outcomes,
• 19:41
  [SPEAKER_01]: Here are the articles from the American Journal of Respiratory and Critical Care Medicine.
• 19:46
  [SPEAKER_01]: One year change in quantitative computed tomography is associated with meaningful outcomes in fibrotic lung disease.
• 19:53
  [SPEAKER_01]: Rational, whether change in fibrosis on high-resolution computed tomography is associated with near and longer term outcomes in patients with fibrotic interstitial lung disease, filled, remains unclear.
• 20:05
  [SPEAKER_01]: Objectives
• 20:06
  [SPEAKER_01]: We evaluated the association between one-year change in quantitative fibrosis scores, data-driven textural analysis, DTA, and subsequent FBC and survival in patients with filled conclusions.
• 20:20
  [SPEAKER_01]: One-year change in DTA score is associated with future disease trajectory and transplant free survival in patients with filled.
• 20:27
  [SPEAKER_01]: DTA could be a useful trial endpoint, cohort enrichment tool,
• 20:40
  [SPEAKER_01]: Next we will be discussing articles in the field of nephrology.
• 20:43
  [SPEAKER_01]: Here are the articles from Clinical Journal of American Society of Nephrology.
• 20:48
  [SPEAKER_01]: The Association of Long COVID and CKD, findings from the National Clinical Cohort Collaborative.
• 20:54
  [SPEAKER_01]: Bassaline CKD, even mild.
• 20:57
  [SPEAKER_01]: is associated with a higher risk of long coronavirus disease, COVID, in patients with acute severe acute respiratory syndrome coronavirus infection.
• 21:07
  [SPEAKER_01]: Among those without CKD at baseline, long COVID is associated with a higher risk of developing new CKD and faster kidney function decline.
• 21:16
  [SPEAKER_01]: Associations between long COVID and CKD slash kidney function decline persist.
• 21:32
  [SPEAKER_01]: Here are the articles from kidney international reports.
• 21:35
  [SPEAKER_01]: Effects of combination treatment on renal endothelial function in type 2 diabetes malitis.
• 21:41
  [SPEAKER_01]: Introduction.
• 21:43
  [SPEAKER_01]: Recently, we demonstrated that a combination therapy with MPa-Glyph Losen and Linniglipton, E plus L, in patients with type 2 diabetes malitis, T2DM, induced changes in renal hemodynamics.
• 21:56
  [SPEAKER_01]: The purpose of the present study was to analyze the influence of nitrogoxide.
• 22:01
  [SPEAKER_01]: No, activity of the renal vasculature on the described changes of the renal hemodynamic profile conclusion.
• 22:08
  [SPEAKER_01]: Renal no activity emerged as a determinant of the renal hemodynamic response in the combination therapy of E plus L, but not in the combination therapy of M plus I.
• 22:19
  [SPEAKER_01]: Our study provides evidence that the treatment effect of sodium glucose co-transporter 2,
• 22:26
  [SPEAKER_01]: Maybe contributed at least partly by the renal no activity in patients with T2DM.
• 22:32
  [SPEAKER_00]: Thank you for listening to this week in medicine, your filtered medical journal summary.
• 22:37
  [SPEAKER_00]: Have a great week ahead, stay blessed and be humane.